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and 2) they raise issues as to the nature of the true stimulus for an
increase in IMA concentrations in patients with chest pain.
There is little doubt, if any, that IMA levels increase during
myocardial ischemia triggered by a primary reduction of blood
flow, as seen in patients during percutaneous coronary intervention
(PCI). Several studies have shown a good correlation among
objective markers of myocardial ischemia, such as lactate levels (4)
isoprostane concentrations (5) and IMA levels, in this setting. We
have therefore suggested that increased IMA levels may result
from increased oxidative stress whether caused by ischemia reper-
fusion injury or other mechanisms linked to primary reductions of
coronary blood flow (5) or muscle damage (6). Indeed, results from
in vitro work from our group support this hypothesis and suggest
that the generation of reactive oxygen species can at least tran-
siently modify the N-terminal region of albumin to yield increased
levels of IMA (7). It is conceivable that the greater the magnitude
of reactive oxygen species formation the higher the elevation of
IMA levels. The production of reactive oxygen species during
balloon occlusion and reperfusion in patients undergoing PCI (8)
and in the acute coronary syndrome setting (9)—where intracoro-
nary thrombosis causes serious reductions in coronary blood
flow—may result in the chemical modification of albumin that
leads to IMA production. Increased oxidative stress production in
these circumstances, together with the lack of antagonistic influ-
ences to IMA measurements that appear to occur during skeletal
muscle exercise (1–3), can explain the consistent finding of
increased IMA levels. Increased oxygen free-radical production,
however, is commonly found in a wide variety of medical condi-
tions other than myocardial ischemia, and this may at least partly
explain both IMA’s baseline variability and relatively low specific-
ity (9).
Further studies are required to understand the mechanisms
leading to increased IMA levels in different clinical conditions of
myocardial ischemia and nonischemic conditions. Moreover, fu-
ture research should be specifically targeted toward identifying the
exact nature of albumin modification and the reasons for the
intriguing findings in relation to exercise, as reported by Sbarouni
et al. (1). Only when these vital mechanisms are elucidated, should
clinical studies be carried out to explore the true potential role of
this marker in clinical practice.
*Debashis Roy, MRCP, MD
Juan Carlos Kaski, MD, DSc, FACC
*Cardiovascular Biology Research Centre
Division of Cardiac and Vascular Sciences
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Reply
We appreciate the interest of Dr. Kalay and colleagues in our study
assessing ischemia-modified albumin (IMA) levels in exercise
stress testing (1). We address their comments:
1. All our patients had angiographically documented coronary
artery disease, the exercise stress test (EST) being part of their
regular follow-up, and the criteria we used for positivity were
rather strict—2-mm horizontal or downsloping ST depression.
In addition, our findings do not differ from Van der Zee et al.
(2), who also observed a significant decrease of IMA plasma
levels at peak exercise and subsequent return to baseline,
without any difference between positive and negative exercise
tests. In that study, single-photon emission computed tomog-
raphy (SPECT) imaging, a more sensitive and specific method
compared to treadmill testing, was used. Therefore, in that
respect, we believe inaccuracies in the EST results (false
positive or negative) cannot be substantiated.
2. Regarding the timing of IMA sampling, percutaneous
coronary intervention (PCI) studies have shown a signifi-
cant increase in IMA plasma levels immediately following
balloon deflation and a return to baseline within 6 to 12 h
(3,4), so we would think that peak exercise is the appropri-
ate time point to assess whether IMA increases in exercise-
induced ischemia.
3. Although we cannot exclude occult peripheral atheroscle-
rosis in our patients, none of the study participants had
clinically significant peripheral vascular disease, by history,
physical examination or clinical presentation. Additionally,
in no patient was the EST limited by skeletal muscle
ischemia, rendering the mechanism of peripheral lactic
acidosis as a cause of decreased exercise IMA levels ex-
tremely unlikely. Furthermore, a very recent report observed
that the rise in IMA plasma levels after PCI parallels that of
transmyocardial lactate, immediately after obstructive bal-
loon inflation (5).
In the letter by Drs. Roy and Kaski regarding our study (1)
they state that IMA decrease at exercise may relate to either
albumin or lactate increase. Albumin plasma levels have been
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assessed during exercise (2) and have been nicely shown to
correlate inversely with IMA changes, in patients with and
without ischemia. Therefore, we believe that the IMA changes
we observed are associated with hemoconcentration. It is well
known that reactive oxygen species production during myocar-
dial ischemia (PCI or acute coronary syndrome) may indeed
induce changes in the amino terminus of albumin. In addition,
we agree that further research regarding specific mechanisms is
necessary.
In conclusion, our study demonstrated that IMA changes
significantly during EST in patients with coronary disease but with
no difference between positive and negative tests; these results, we
believe, imply that IMA changes may not relate to myocardial
ischemia.
*Eftihia Sbarouni, MD, FESC
Panagiota Georgiadou, MD
George N. Theodorakis, MD, FESC
Dimitrios Th. Kremastinos, MD, FESC
*Onassis Cardiac Surgery Center
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